Hyperthyroidism
Conditions
Keywords
hyperthyroidism, heart rate variability, propanolol, Africa
Brief summary
Objective: The aim of our study was to evaluate the short term effects of Propanolol on heart rate variability in patients with hyperthyroidism. Design: In ten patients newly diagnosed as having hyperthyroidism and naïve of all treatment specific for hyperthyroidism, we evaluated the short term effects of Propanolol on heart rate variability (HRV). Methods: We measured heart rate variability by power spectral analysis during 2 hours of rest and during Ewing's tests before and after the administration of Propanolol 40mg/12 hours orally for 72 hours.
Detailed description
Objective: The aim of our study was to evaluate the short term effects of Propanolol on heart rate variability in patients with hyperthyroidism. Design: In ten patients newly diagnosed as having hyperthyroidism and naïve of all treatment specific for hyperthyroidism, we evaluated the short term effects of Propanolol on heart rate variability (HRV). Methods: We measured heart rate variability by power spectral analysis during 2 hours of rest and during Ewing's tests before and after the administration of Propanolol 40mg/12 hours orally for 72 hours. Other outcomes included mean heart rate, mean R-R interval during 2-hour rest. The study questions the systematic adjunction of Propanolol early in the treatment of hyperthyroidism.
Interventions
DRUGPropanolol
72-hour propanolol before specific treatment of hyperthyroidism
Sponsors
Yaounde Central Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Open label Before and After design
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* consenting patients referred to or diagnosed at the National Centre of Obesity of the Yaounde Central Hospital as having hyperthyroidism * naïve of all treatment specific for hyperthyroidism. * aged 18-70 years
Exclusion criteria
* Patients already under a specific treatment for hyperthyroidism * Patients taking beta blockers or any other cardiospecific treatment * Patients presenting complications including acute thyrotoxic crisis, or symptomatic cardiac failure * Contraindications to the prescription of beta blockers
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Heart rate variability | 72 hours | Sympatho vagal tone measures |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Heart rate | 72 hours | Heart rate |
Outcome results
None listed